Dongwoon AnaTech is showing strength, rising more than 7% during the trading session on the 29th. This is interpreted as a result of improved investor sentiment after Eugene Investment & Securities released a new analysis report anticipating improved second-half performance and the full-scale launch of the medical device business.

During the session on this day, Dongwoon AnaTech traded at 32,050 won, up 2,100 won (approximately 7%) from the previous trading day. The upward trend continued as buying interest flowed in from the early part of the session.

Eugene Investment & Securities published a report on this day titled 'NDR Takeaways: Expectations for Second-Half Performance Recovery and Medical Device Business.' The investment opinion was presented as Not Rated.

■ Forecast for Second-Half IT Performance Recovery

The report assessed that while the IT business division's performance was sluggish in the first half, it is highly likely to enter a recovery phase from the second half. It projected that an earnings improvement trend would emerge alongside a recovery in demand from major clients.

However, short-term concerns remain. Eugene Investment & Securities expected continued weak performance in the second quarter but anticipated that the timing of improvement would become clearer in the second half.

■ Medical Device Business Emerges as Key Variable

The medical device business was presented as a new growth driver. Dongwoon AnaTech plans to fully expand its medical device business in the second half, including pursuing the Ministry of Food and Drug Safety's Investigational Device Exemption (IDE) procedure. It was analyzed that progress in the related business would become an important variable for future corporate value.

Additionally, with the projected price-to-earnings ratio (PER) for 2026 standing at around 62.6 times, the company is being valued at a premium compared to industry peers. Whether earnings improvements can support the current valuation was highlighted as a key point to watch.

The market is closely watching whether second-half IT recovery and progress in the medical device business can translate into actual results, which could lead to a revaluation of corporate value, while also noting that delays in performance recovery could increase stock price volatility.

[※ This article is not intended to solicit investment. The final judgment and responsibility for all investments lie with the investor.]